

Adrenal crises

| | | |
|-------------------|------------------|---|
| Management | Severally unwell | <p>Based on Severity: Severe / Moderate / Mild</p> <p>1. Stabilization (ABC)</p> <ul style="list-style-type: none"> Ensure airway, breathing, circulation. <p>2. Steroid Replacement</p> <ul style="list-style-type: none"> Severely unwell: <ul style="list-style-type: none"> IV hydrocortisone 50–100 mg/m² immediately. If IV unavailable → IM dose while establishing IV access. Repeat dose if poor response. Then hydrocortisone 6-hourly IV. Switch to oral triple dose (~30–50 mg/m²/day) once stable, gradually taper to maintenance. Mineralocorticoid replacement: fludrocortisone 0.05–0.1 mg/day orally once tolerating fluids. <p>3. Intravenous Fluids</p> <ul style="list-style-type: none"> Shock / moderate-severe dehydration: 0.9% NaCl 10–20 mL/kg first hour; repeat as needed. Replace deficit + maintenance over 24h with 0.9% NaCl + 5% glucose. Mild/no dehydration: 1–1.5 × maintenance fluid over 24h. <p>4. Hypoglycemia</p> <ul style="list-style-type: none"> IV 10% dextrose 2–5 mL/kg. Recheck after 30 min; continue maintenance fluids with up to 10% dextrose as needed. <p>5. Treat Precipitating Illness/Injury</p> <ul style="list-style-type: none"> Identify & manage infection, trauma, surgery, or other triggers. |
|-------------------|------------------|---|

| Recommended stress hydrocortisone dose | <p>Glucocorticoid “Stress Doses” (if no sick-day plan)</p> <ul style="list-style-type: none"> Mild illness: 20 mg/m²/day. Moderate illness / fever >38°C / vomiting/diarrhea: 30 mg/m²/day + ↑ fluids & carbs. Severe illness / shock / vomiting, diarrhea, drowsy: IV/IM hydrocortisone 50–100 mg/m², follow as above. | | | | | | | | | | | | | | | |
|--|---|--|--------------------------------------|------------------------------------|-------------------|-------|-----------|-----------------|-------|-------|----------------|-------|--|-----------|--------|-------|
| | <table border="1" style="width: 100%;"> <thead> <tr> <th>Age</th> <th>Initial dose of IM/IV hydrocortisone</th> <th>THEN hydrocortisone every 6 hours*</th> </tr> </thead> <tbody> <tr> <td>Neonate – 6 weeks</td> <td>25 mg</td> <td>5 – 10 mg</td> </tr> <tr> <td>6 weeks – 3 yrs</td> <td>25 mg</td> <td>10 mg</td> </tr> <tr> <td>3 yrs – 12 yrs</td> <td>50 mg</td> <td>12.5 mg ages 3-6 yo 25 mg ages 6-12 yo</td> </tr> <tr> <td>≥12 years</td> <td>100 mg</td> <td>25 mg</td> </tr> </tbody> </table> <div style="background-color: #c8e6c9; padding: 5px; text-align: center; font-weight: bold; margin-top: 5px;"> Recommended doses of 'Stress' Hydrocortisone (given IM or IV) by age: </div> | Age | Initial dose of IM/IV hydrocortisone | THEN hydrocortisone every 6 hours* | Neonate – 6 weeks | 25 mg | 5 – 10 mg | 6 weeks – 3 yrs | 25 mg | 10 mg | 3 yrs – 12 yrs | 50 mg | 12.5 mg ages 3-6 yo 25 mg ages 6-12 yo | ≥12 years | 100 mg | 25 mg |
| Age | Initial dose of IM/IV hydrocortisone | THEN hydrocortisone every 6 hours* | | | | | | | | | | | | | | |
| Neonate – 6 weeks | 25 mg | 5 – 10 mg | | | | | | | | | | | | | | |
| 6 weeks – 3 yrs | 25 mg | 10 mg | | | | | | | | | | | | | | |
| 3 yrs – 12 yrs | 50 mg | 12.5 mg ages 3-6 yo 25 mg ages 6-12 yo | | | | | | | | | | | | | | |
| ≥12 years | 100 mg | 25 mg | | | | | | | | | | | | | | |

Prevention Children with known adrenal insufficiency will have an individualised sick day management plan. This should be followed in the first instance. The following guidance is for when there is no sick day plan available

| | |
|------------------------|---|
| Addison disease | <p>Addison's Disease (Primary Adrenal Insufficiency)</p> <p>Clinical Presentation</p> <ul style="list-style-type: none"> Hyperpigmentation Salt craving Postural hypotension Fasting hypoglycemia Anorexia, weakness Episodes of shock during severe illness. <p>Diagnostic Findings</p> <ul style="list-style-type: none"> Subnormal baseline & ACTH-stimulated cortisol. Hyponatremia, hyperkalemia, ↑ plasma renin → mineralocorticoid deficiency. <p>Associated Conditions</p> <ul style="list-style-type: none"> Autoimmune polyglandular syndromes. Rare causes: <ul style="list-style-type: none"> X-linked adrenal leukodystrophy. Hypothalamic-pituitary disorders (e.g., craniopharyngioma). Iatrogenic (radiation for malignancy). |
|------------------------|---|

Dx:

Diagnosis of Adrenal Insufficiency

Patient presents with signs or symptoms of adrenal insufficiency

Order basic metabolic panel and measurement of 8 a.m. serum cortisol level

Results inconsistent with adrenal insufficiency → Consider other diagnoses

Low cortisol level, Normal to high potassium level, Low to normal sodium level → Perform cosyntropin stimulation test: measure basal ACTH level before administering intravenous ACTH (250 mcg); measure cortisol level again after 30 and 60 minutes after administration

Normal cosyntropin test result → Consider other diagnoses

Low cortisol level, High ACTH level → Primary adrenal insufficiency

Low cortisol level, Low ACTH level → Secondary adrenal insufficiency

To identify etiology: Measure 21-hydroxylase antibody level, Perform computed tomography of adrenal gland

Mx:


- Replacement treatment with 10–15 mg/m² per 24 hours of hydrocortisone is indicated, with supplementation during stress at three times the maintenance dosage or the use of intramuscular hydrocortisone. The dose is titrated to allow a normal growth rate. Mineralocorticoid replacement with fludrocortisone is monitored by plasma renin activity along with serum sodium and potassium determinations.

| Congenital adrenal hyperplasia (ACH) | |
|--------------------------------------|--|
| Overview of hormone synthesis | <p>Adrenal Steroid Synthesis: First Steps</p> <ul style="list-style-type: none"> Cholesterol → Pregnenolone via cholesterol desmolase (first step for all adrenal hormones). Zona glomerulosa (aldosterone production): <ol style="list-style-type: none"> Pregnenolone → Progesterone (3β-HSD) Progesterone → 11-deoxycorticosterone (21-hydroxylase) 11-deoxycorticosterone → Corticosterone (11β-hydroxylase) Corticosterone → Aldosterone (aldosterone synthase) Zona fasciculata (cortisol production): <ol style="list-style-type: none"> Pregnenolone → 17-hydroxypregnenolone (17α-hydroxylase) Progesterone → 17-hydroxyprogesterone (17α-hydroxylase) 17-hydroxyprogesterone → 11-deoxycortisol (21-hydroxylase) 11-deoxycortisol → Cortisol (11β-hydroxylase) Zona reticularis (androgens): <ol style="list-style-type: none"> 17-hydroxypregnenolone → DHEA (17,20-lyase) 17-hydroxyprogesterone → Androstenedione (17,20-lyase) DHEA → Androstenedione (3β-HSD) Androstenedione & DHEA → Testosterone |


| 21-Hydroxylase Deficiency (Most Common CAH, >90%) | |
|---|---|
| Types | <ol style="list-style-type: none"> Classic CAH: early infancy/childhood <ul style="list-style-type: none"> Salt-wasting form: cortisol + aldosterone deficiency → adrenal crisis Simple virilizing form: cortisol deficiency only, no salt loss Non-classic CAH: mild, presents later in childhood/adolescence |
| Clinical Features: | <ul style="list-style-type: none"> Females: clitoromegaly, urogenital sinus, partial/complete labial fusion; internal organs normal Males: normal external genitalia, subtle hyperpigmentation, enlarged phallus Salt-wasting: hyponatremia, hyperkalemia, failure to thrive Simple virilizing: premature pubic/axillary hair in boys |
| Diagnosis | <ul style="list-style-type: none"> Neonatal screening: 17-hydroxyprogesterone >1000 ng/mL Karyotype: confirm genetic sex in ambiguous genitalia |
| Management | <ul style="list-style-type: none"> Lifelong glucocorticoids (hydrocortisone) → suppress ACTH, prevent adrenal hyperplasia & androgen excess Mineralocorticoids (fludrocortisone), even in non-salt-wasting form Surgery for females (clitoroplasty/vaginoplasty) |
| Monitoring: | <ul style="list-style-type: none"> Serum 17-hydroxyprogesterone, androstenedione Blood pressure, plasma renin activity Growth velocity & bone age (prevent early epiphyseal closure) ← <i>glucocorticoid = premature closure</i> |
| Non-Classic 21-Hydroxylase Deficiency | <ul style="list-style-type: none"> Milder form: females present with primary amenorrhea, hirsutism, acne, polycystic ovaries in adolescence Males may show precocious puberty Usually no stress glucocorticoid doses needed unless on chronic therapy |

| Other Rare CAH Enzyme Deficiencies (<10%) | |
|---|---|
| 17-alpha-hydroxylase deficiency | <ul style="list-style-type: none"> ↓ Cortisol & androgens → ↑ 11-deoxycorticosterone & corticosterone → hypertension, hypernatremia, hypokalemia Females: primary amenorrhea, sparse body hair Males: undervirilization Diagnosis: high 11-deoxycorticosterone/corticosterone, low cortisol/androgens Management: glucocorticoids; females: estrogen + progestin; males: testosterone |
| 11 beta hydroxylase deficiency. | <ul style="list-style-type: none"> ↓ Cortisol, mild ↓ aldosterone, ↑ 11-deoxycorticosterone → hypertension Excess DHEA → virilization in females Neonatal females: ambiguous genitalia; males: enlarged phallus Diagnosis: ↑11-deoxycortisol, 11-deoxycorticosterone, testosterone, hypokalemia Management: hydrocortisone; adult females: add spironolactone; adult males: amiloride/triamterene |
| 3-beta-hydroxysteroid-dehydrogenase deficiency. | <ul style="list-style-type: none"> Rare; ↓ all adrenal hormones → ACTH ↑ → ↑ Δ5 steroids (pregnenolone, 17-hydroxypregnenolone, DHEA) Both sexes: ambiguous genitalia at birth Diagnosis: high Δ5/Δ4 steroid ratio Management: replace adrenal & gonadal steroids; puberty: estrogen/progestin in females, testosterone in males |

Major Pathway for Adrenal Steroid Synthesis



• salt + water retention \rightarrow Adrenal crisis



21 هو جبر الأنتال
في الخط الصاعدي الواحد

17 هو خط الوهل
بين ال16 وال21

